Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Colonoscopy Indication Algorithm Performance Across Diverse Health Care Systems in the PROSPR Consortium.

Burnett-Hartman AN, Kamineni A, Corley DA, Singal AG, Halm EA, Rutter CM, Chubak J, Lee JK, Doubeni CA, Inadomi JM, Doria-Rose VP, Zheng Y.

EGEMS (Wash DC). 2019 Aug 2;7(1):37. doi: 10.5334/egems.296.

2.

Factors associated with employment discontinuation among older and working age survivors of oropharyngeal cancer.

Check DK, Hutcheson KA, Poisson LM, Pocobelli G, Sakoda LC, Zaveri J, Chang SS, Chubak J.

Head Neck. 2019 Sep 6. doi: 10.1002/hed.25943. [Epub ahead of print]

PMID:
31490588
3.

Symptom Burden in Long-Term Survivors of Head and Neck Cancer: Patient-Reported Versus Clinical Data.

Pocobelli G, Ziebell R, Fujii M, Hutcheson KA, Chang S, McClure JB, Chubak J.

EGEMS (Wash DC). 2019 Jul 10;7(1):25. doi: 10.5334/egems.271.

4.

Evaluating screening participation, follow-up and outcomes for breast, cervical and colorectal cancer in the PROSPR consortium.

Barlow WE, Beaber EF, Geller BM, Kamineni A, Zheng Y, Haas JS, Chao CR, Rutter CM, Zauber AG, Sprague BL, Halm EA, Weaver DL, Chubak J, Doria-Rose VP, Kobrin S, Onega T, Quinn VP, Schapira MM, Tosteson ANA, Corley DA, Skinner CS, Schnall MD, Armstrong K, Wheeler CM, Silverberg MJ, Balasubramanian BA, Doubeni CA, McLerran D, Tiro JA.

J Natl Cancer Inst. 2019 Jul 11. pii: djz137. doi: 10.1093/jnci/djz137. [Epub ahead of print]

PMID:
31292633
5.

The association between colorectal sessile serrated adenomas/polyps and subsequent advanced colorectal neoplasia.

Burnett-Hartman AN, Chubak J, Hua X, Ziebell R, Kamineni A, Zhu LC, Upton MP, Malen RC, Hardikar S, Newcomb PA.

Cancer Causes Control. 2019 Sep;30(9):979-987. doi: 10.1007/s10552-019-01205-y. Epub 2019 Jul 9.

6.

Financial Incentives to Increase Colorectal Cancer Screening Uptake and Decrease Disparities: A Randomized Clinical Trial.

Green BB, Anderson ML, Cook AJ, Chubak J, Fuller S, Kimbel KJ, Kullgren JT, Meenan RT, Vernon SW.

JAMA Netw Open. 2019 Jul 3;2(7):e196570. doi: 10.1001/jamanetworkopen.2019.6570.

PMID:
31276178
7.

Treatment patterns and survival differ between early-onset and late-onset colorectal cancer patients: the patient outcomes to advance learning network.

Burnett-Hartman AN, Powers JD, Chubak J, Corley DA, Ghai NR, McMullen CK, Pawloski PA, Sterrett AT, Feigelson HS.

Cancer Causes Control. 2019 Jul;30(7):747-755. doi: 10.1007/s10552-019-01181-3. Epub 2019 May 17.

PMID:
31102084
8.

Time to Follow-up After Colorectal Cancer Screening by Health Insurance Type.

Breen N, Skinner CS, Zheng Y, Inrig S, Corley DA, Beaber EF, Garcia M, Chubak J, Doubeni C, Quinn VP, Haas JS, Li CI, Wernli KJ, Klabunde CN; PROSPR consortium.

Am J Prev Med. 2019 May;56(5):e143-e152. doi: 10.1016/j.amepre.2019.01.005.

PMID:
31003603
9.

Time to fecal immunochemical test completion for colorectal cancer screening.

Haas CB, Phipps AI, Hajat A, Chubak J, Wernli KJ.

Am J Manag Care. 2019 Apr;25(4):174-180.

10.

Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients.

Clarke CL, Kushi LH, Chubak J, Pawloski PA, Bulkley JE, Epstein MM, Burnett-Hartman AN, Powell B, Pearce CL, Spencer Feigelson H.

Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):996-999. doi: 10.1158/1055-9965.EPI-18-1324. Epub 2019 Apr 9.

PMID:
30967418
11.

Risk of second breast cancer events with chronic opioid use in breast cancer survivors.

Boudreau DM, Chen L, Yu O, Bowles EJA, Chubak J.

Pharmacoepidemiol Drug Saf. 2019 May;28(5):740-753. doi: 10.1002/pds.4779. Epub 2019 Apr 3.

PMID:
30945381
12.

Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study.

Bowles EJA, Yu O, Ziebell R, Chen L, Boudreau DM, Ritzwoller DP, Hubbard RA, Boggs JM, Burnett-Hartman AN, Sterrett A, Fujii M, Chubak J.

BMC Cancer. 2019 Mar 27;19(1):270. doi: 10.1186/s12885-019-5493-8.

13.

Cognitive Resilience to Alzheimer's Disease Pathology in the Human Brain.

Aiello Bowles EJ, Crane PK, Walker RL, Chubak J, LaCroix AZ, Anderson ML, Rosenberg D, Keene CD, Larson EB.

J Alzheimers Dis. 2019;68(3):1071-1083. doi: 10.3233/JAD-180942.

PMID:
30909217
14.

Use of antidepressants after colon cancer diagnosis and risk of recurrence.

Pocobelli G, Yu O, Ziebell RA, Aiello Bowles EJ, Fujii MM, Sterrett AT, Boggs JM, Chen L, Boudreau DM, Ritzwoller DP, Hubbard RA, Chubak J.

Psychooncology. 2019 Apr;28(4):750-758. doi: 10.1002/pon.5015. Epub 2019 Feb 14.

PMID:
30703275
15.

CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy.

Mayer SE, Weiss NS, Chubak J, Doody DR, Carlson CS, Makar KW, Wurscher MA, Malone KE.

Cancer Causes Control. 2019 Jan;30(1):103-112. doi: 10.1007/s10552-018-1117-x. Epub 2018 Dec 12.

PMID:
30542984
16.

Receipt of Colonoscopy Following Diagnosis of Advanced Adenomas: An Analysis within Integrated Healthcare Delivery Systems.

Chubak J, McLerran D, Zheng Y, Singal AG, Corley DA, Doria-Rose VP, Doubeni CA, Kamineni A, Haas JS, Halm EA, Skinner CS, Zauber AG, Wernli KJ, Beaber EF; PROSPR consortium.

Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):91-98. doi: 10.1158/1055-9965.EPI-18-0452. Epub 2018 Nov 20.

PMID:
30459208
17.

Inflation of type I error rates due to differential misclassification in EHR-derived outcomes: Empirical illustration using breast cancer recurrence.

Chen Y, Wang J, Chubak J, Hubbard RA.

Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):264-268. doi: 10.1002/pds.4680. Epub 2018 Oct 30.

18.

Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort.

Kamineni A, Tiro JA, Beaber EF, Silverberg MJ, Wheeler CM, Chao CR, Chubak J, Skinner CS, Corley DA, Kim JJ, Balasubramanian BA, Paul Doria-Rose V; PROSPR consortium.

Int J Cancer. 2019 Mar 15;144(6):1460-1473. doi: 10.1002/ijc.31940. Epub 2018 Dec 20.

PMID:
30353911
19.

Risk of colon cancer recurrence in relation to diabetes.

Chubak J, Yu O, Ziebell RA, Bowles EJA, Sterrett AT, Fujii MM, Boggs JM, Burnett-Hartman AN, Boudreau DM, Chen L, Floyd JS, Ritzwoller DP, Hubbard RA.

Cancer Causes Control. 2018 Nov;29(11):1093-1103. doi: 10.1007/s10552-018-1083-3. Epub 2018 Sep 22.

PMID:
30244297
20.

Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study.

Selby K, Jensen CD, Lee JK, Doubeni CA, Schottinger JE, Zhao WK, Chubak J, Halm E, Ghai NR, Contreras R, Skinner C, Kamineni A, Levin TR, Corley DA.

Ann Intern Med. 2018 Oct 2;169(7):439-447. doi: 10.7326/M18-0244. Epub 2018 Sep 18.

21.

Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States.

Singal AG, Corley DA, Kamineni A, Garcia M, Zheng Y, Doria-Rose PV, Quinn VP, Jensen CD, Chubak J, Tiro J, Doubeni CA, Ghai NR, Skinner CS, Wernli K, Halm EA.

Am J Gastroenterol. 2018 May;113(5):746-754. doi: 10.1038/s41395-018-0023-x. Epub 2018 Feb 27.

22.

Financial difficulty, worry about affording care, and benefit finding in long-term survivors of cancer.

Jones SMW, Walker R, Fujii M, Nekhlyudov L, Rabin BA, Chubak J.

Psychooncology. 2018 Apr;27(4):1320-1326. doi: 10.1002/pon.4677. Epub 2018 Mar 8.

PMID:
29462511
23.

An Electronic Health Record-based Algorithm to Ascertain the Date of Second Breast Cancer Events.

Chubak J, Onega T, Zhu W, Buist DSM, Hubbard RA.

Med Care. 2017 Dec;55(12):e81-e87. doi: 10.1097/MLR.0000000000000352.

24.

Accounting for misclassification in electronic health records-derived exposures using generalized linear finite mixture models.

Hubbard RA, Johnson E, Chubak J, Wernli KJ, Kamineni A, Bogart A, Rutter CM.

Health Serv Outcomes Res Methodol. 2017 Jun;17(2):101-112. doi: 10.1007/s10742-016-0149-5. Epub 2016 Jun 3.

25.

Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis.

Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI.

Cancer Res. 2017 Nov 1;77(21):6033-6041. doi: 10.1158/0008-5472.CAN-17-0687. Epub 2017 Sep 21.

26.

Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population.

Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI.

Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1603-1610. doi: 10.1158/1055-9965.EPI-17-0346. Epub 2017 Aug 14.

27.

A centralized mailed program with stepped increases of support increases time in compliance with colorectal cancer screening guidelines over 5 years: A randomized trial.

Green BB, Anderson ML, Cook AJ, Chubak J, Fuller S, Meenan RT, Vernon SW.

Cancer. 2017 Nov 15;123(22):4472-4480. doi: 10.1002/cncr.30908. Epub 2017 Jul 28.

28.

Pilot Study of Therapy Dog Visits for Inpatient Youth With Cancer.

Chubak J, Hawkes R, Dudzik C, Foose-Foster JM, Eaton L, Johnson RH, Macpherson CF.

J Pediatr Oncol Nurs. 2017 Sep/Oct;34(5):331-341. doi: 10.1177/1043454217712983. Epub 2017 Jun 14.

PMID:
28614971
29.

Cohort restriction based on prior enrollment: Examining potential biases in estimating cancer and mortality risk.

Shortreed SM, Johnson E, Rutter CM, Kamineni A, Wernli KJ, Chubak J.

Obs Stud. 2016 Aug;2:51-64. Epub 2016 Sep 26.

30.

Cancer Survivors' Reported Discussions with Health Care Providers About Follow-Up Care and Receipt of Written Care Plans.

Reed SC, Walker R, Ziebell R, Rabin B, Nutt S, Chubak J, Nekhlyudov L.

J Cancer Educ. 2018 Dec;33(6):1181-1188. doi: 10.1007/s13187-017-1228-1.

PMID:
28480500
31.

Reproductive factors and risk of colorectal polyps in a colonoscopy-based study in western Washington State.

Hardikar S, Burnett-Hartman AN, Chubak J, Upton MP, Zhu LC, Potter JD, Newcomb PA.

Cancer Causes Control. 2017 Mar;28(3):241-246. doi: 10.1007/s10552-017-0866-2. Epub 2017 Feb 15.

32.

Association of worry about cancer to benefit finding and functioning in long-term cancer survivors.

Jones SM, Ziebell R, Walker R, Nekhlyudov L, Rabin BA, Nutt S, Fujii M, Chubak J.

Support Care Cancer. 2017 May;25(5):1417-1422. doi: 10.1007/s00520-016-3537-z. Epub 2016 Dec 15.

PMID:
27981365
33.

Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System.

Singal AG, Tiro J, Li X, Adams-Huet B, Chubak J.

J Clin Gastroenterol. 2017 Aug;51(7):650-655. doi: 10.1097/MCG.0000000000000708.

34.

Cancer survivors' experiences with insurance, finances, and employment: results from a multisite study.

Nekhlyudov L, Walker R, Ziebell R, Rabin B, Nutt S, Chubak J.

J Cancer Surviv. 2016 Dec;10(6):1104-1111. Epub 2016 Jun 9.

PMID:
27277896
35.

The Cancer Research Network: a platform for epidemiologic and health services research on cancer prevention, care, and outcomes in large, stable populations.

Chubak J, Ziebell R, Greenlee RT, Honda S, Hornbrook MC, Epstein M, Nekhlyudov L, Pawloski PA, Ritzwoller DP, Ghai NR, Feigelson HS, Clancy HA, Doria-Rose VP, Kushi LH.

Cancer Causes Control. 2016 Nov;27(11):1315-1323. Epub 2016 Sep 17.

36.

The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.

Drescher CW, Beatty JD, Resta R, Andersen MR, Watabayashi K, Thorpe J, Hawley S, Purkey H, Chubak J, Hanson N, Buist DSM, Urban N.

Cancer. 2016 Nov 15;122(22):3509-3518. doi: 10.1002/cncr.30190. Epub 2016 Jul 22.

37.

Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly.

Klabunde CN, Zheng Y, Quinn VP, Beaber EF, Rutter CM, Halm EA, Chubak J, Doubeni CA, Haas JS, Kamineni A, Schapira MM, Vacek PM, Garcia MP, Corley DA; PROSPR consortium.

Am J Prev Med. 2016 Sep;51(3):e67-75. doi: 10.1016/j.amepre.2016.04.018. Epub 2016 Jun 22.

38.

Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.

Halm EA, Beaber EF, McLerran D, Chubak J, Corley DA, Rutter CM, Doubeni CA, Haas JS, Balasubramanian BA.

J Gen Intern Med. 2016 Oct;31(10):1190-7. doi: 10.1007/s11606-016-3760-9. Epub 2016 Jun 8.

39.

Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity.

McCarthy AM, Kim JJ, Beaber EF, Zheng Y, Burnett-Hartman A, Chubak J, Ghai NR, McLerran D, Breen N, Conant EF, Geller BM, Green BB, Klabunde CN, Inrig S, Skinner CS, Quinn VP, Haas JS, Schnall M, Rutter CM, Barlow WE, Corley DA, Armstrong K, Doubeni CA; PROSPR consortium.

Am J Prev Med. 2016 Oct;51(4):507-12. doi: 10.1016/j.amepre.2016.03.017. Epub 2016 Apr 28.

40.

Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force.

Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DS, Anderson ML.

Ann Intern Med. 2016 Jun 21;164(12):814-25. doi: 10.7326/M15-2117. Epub 2016 Apr 12. Review.

PMID:
27064482
41.

Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems.

Burnett-Hartman AN, Mehta SJ, Zheng Y, Ghai NR, McLerran DF, Chubak J, Quinn VP, Skinner CS, Corley DA, Inadomi JM, Doubeni CA; PROSPR Consortium.

Am J Prev Med. 2016 Oct;51(4):e107-15. doi: 10.1016/j.amepre.2016.02.025. Epub 2016 Apr 1.

42.

Colorectal Cancer Screening Rates Increased after Exposure to the Patient-Centered Medical Home (PCMH).

Green BB, Anderson ML, Chubak J, Baldwin LM, Tuzzio L, Catz S, Cole A, Vernon SW.

J Am Board Fam Med. 2016 Mar-Apr;29(2):191-200. doi: 10.3122/jabfm.2016.02.150290.

43.

Defining and measuring adherence to cancer screening.

Chubak J, Hubbard R.

J Med Screen. 2016 Dec;23(4):179-185. Epub 2016 Mar 4.

44.

Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems.

Chubak J, Garcia MP, Burnett-Hartman AN, Zheng Y, Corley DA, Halm EA, Singal AG, Klabunde CN, Doubeni CA, Kamineni A, Levin TR, Schottinger JE, Green BB, Quinn VP, Rutter CM; PROSPR consortium.

Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):344-50. doi: 10.1158/1055-9965.EPI-15-0470.

45.

Statistical Methods for Estimating the Cumulative Risk of Screening Mammography Outcomes.

Hubbard RA, Ripping TM, Chubak J, Broeders MJ, Miglioretti DL.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):513-20. doi: 10.1158/1055-9965.EPI-15-0824. Epub 2015 Dec 31.

46.

Animal-Assisted Activities: Results From a Survey of Top-Ranked Pediatric Oncology Hospitals.

Chubak J, Hawkes R.

J Pediatr Oncol Nurs. 2016 Jul;33(4):289-96. doi: 10.1177/1043454215614961. Epub 2015 Nov 20.

47.

Enhancing Breast Cancer Recurrence Algorithms Through Selective Use of Medical Record Data.

Kroenke CH, Chubak J, Johnson L, Castillo A, Weltzien E, Caan BJ.

J Natl Cancer Inst. 2015 Nov 18;108(3). pii: djv336. doi: 10.1093/jnci/djv336. Print 2016 Mar. Erratum in: J Natl Cancer Inst. 2016 Mar;108(3). pii: djw025. doi: 10.1093/jnci/djw025. J Natl Cancer Inst. 2016 Mar;108(3). pii: djw017. doi: 10.1093/jnci/djw017.

48.

Breast cancer recurrence in relation to antidepressant use.

Chubak J, Bowles EJ, Yu O, Buist DS, Fujii M, Boudreau DM.

Cancer Causes Control. 2016 Jan;27(1):125-36. doi: 10.1007/s10552-015-0689-y. Epub 2015 Oct 30.

49.

Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Chubak J, Kamineni A, Buist DSM, Anderson ML, Whitlock EP.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep.

50.

Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial.

Green BB, Anderson ML, Chubak J, Fuller S, Meenan RT, Vernon SW.

Cancer. 2016 Jan 15;122(2):312-21. doi: 10.1002/cncr.29734. Epub 2015 Oct 21.

Supplemental Content

Loading ...
Support Center